Orphalan's Strategic Partnership for Wilson's Disease
Orphalan is making history in the realm of rare diseases by teaming up with SPH Kyuan Trade, a significant player in pharmaceutical distribution. This partnership is designed to greatly improve access to treatment for Wilson's disease patients, marking a crucial advancement for healthcare in the region.
A Landmark Achievement
With the introduction of its innovative treatment, "Ke Pei Ou" (???®), Orphalan has officially entered the Wilson's disease market in China, becoming the first European company to do so. This is a monumental step for Orphalan and signifies a broader commitment to enhancing the lives of those afflicted by rare diseases globally.
The Journey Toward Improved Patient Care
Wilson's disease is a rare genetic disorder that leads to toxic copper accumulation in the body, potentially resulting in severe neurological and liver complications. Traditional treatments, such as penicillamine, are not tolerated by all patients, leaving a gap in available therapies. Orphalan’s product, trientine tetrahydrochloride, offers a new hope in this context, providing alternatives to those who face treatment barriers.
Revolutionizing Treatment Options
Approved by the National Medical Products Administration (NMPA), "Ke Pei Ou" is the inaugural trientine treatment available in China. Previously available in over 20 countries, this new entry is anticipated to transform the therapeutic landscape for Wilson's disease patients, potentially improving their quality of life significantly.
Expanding Presence in the Region
Understanding the importance of having a localized approach, Orphalan has established an office in Shanghai and appointed Ms. Grace Li as the General Manager. This strategic decision aims to solidify Orphalan's presence in the Chinese market while enhancing its interactions with healthcare professionals.
Key Initiatives for Local Engagement
Ms. Li’s responsibilities include fostering connections with healthcare professionals, facilitating comprehensive education on Wilson's disease management, and reinforcing Orphalan's role within the Chinese healthcare system.
Commitment to Innovation and Access
Orphalan's efforts represent more than just market expansion; they signify a profound commitment to improving access to critical treatments. Dr. Naseem Amin, CEO of Orphalan, emphasized the transformative nature of these developments: "This launch is not just about sales; it's a breakthrough for patients, especially those suffering from rare diseases in regions where treatment options are scarce."
The Future of Rare Disease Care
As Orphalan continues its mission of enhancing global healthcare accessibility, patients in China will benefit from their innovative approaches, leading to significantly improved outcomes in Wilson's disease management. With insights from medical professionals and active integration into healthcare practices, Orphalan is paving the way forward.
About Orphalan
Founded in 2011, Orphalan is dedicated to developing and delivering effective treatments for individuals with rare diseases. Headquartered in Paris, the company collaborates with various stakeholders in the scientific community to meet the challenges faced by patients worldwide.
Contact Information
For further inquiries, please reach out to:
Orphalan
Géraldine van den Broek, Head of Corporate & BD
Tel: +33 (0)1 42 49 82 64
Email: info@orphalan.com
Frequently Asked Questions
What is the significance of Orphalan launching its treatment in China?
This launch marks Orphalan as the first European company to introduce a Wilson's disease treatment in China, expanding access for patients.
What is Wilson's disease?
Wilson's disease is a genetic disorder that prevents proper copper elimination from the body, leading to various health issues if untreated.
How does Orphalan's treatment differ from previous options?
Unlike traditional therapies, Orphalan's product offers a viable alternative for patients who cannot tolerate existing treatments.
Who is overseeing Orphalan's efforts in China?
Ms. Grace Li has been appointed as General Manager to guide the company's initiatives within the region.
What does this launch mean for the future of rare disease treatment?
This launch indicates a growing commitment to addressing the unmet medical needs of patients suffering from rare diseases, ensuring better care and access moving forward.
